• Explore /
  • Poster
  • / ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).

ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).

Abstract Poster

Authors

null

Desmond Yip

The Canberra Hospital, Canberra, Australia

Desmond Yip , John Raymond Zalcberg , Jean-Yves Blay , Mikael Eriksson , David Espinoza , Timothy Jay Price , Sandrine Marreaud , Antoine Italiano , Neeltje Steeghs , Kjetil Boye , Craig Underhill , Sayeda Naher , Martinus Oostendorp , Val Gebski , John Simes , Hans Gelderblom , Heikki Joensuu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Registration Number

ACTRN12614000950662

Citation

J Clin Oncol 37, 2019 (suppl; abstr 11023)

DOI

10.1200/JCO.2019.37.15_suppl.11023

Abstract #

11023

Poster Bd #

346

Abstract Disclosures

Similar Posters

First Author: Axel Le Cesne

First Author: Yoon-Koo Kang

First Author: Heikki Joensuu

First Author: D. Wang